Dear readers,

With “memo inOncology” Springer has created a medical education platform that is globally accessible and offers value to health care professionals in oncology (www.memoinoncology.com).

Over the last four years, we have reported from major conferences such as ASCO, ESMO, WCLC, ELCC or ESMO Asia on recent highlights in the field of lung cancer. Our congress reports and translations thereof into Mandarin and Japanese have received great international interest. Hence, we have decided to expand on this success and create additional content on other solid tumors. This issue covers novel clinical research on anti-PD-1 treatment, a potential role of the microbiome in tumorigenesis as well as PARP inhibition in gynecological cancers and beyond. We hope that you will enjoy reading this report and find it useful.

Dr. Alois Sillaber
Managing Director
Springer-Verlag GmbH
Springer Nature